Real-world, retrospective study of efficacy and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Latest Information Update: 17 Jun 2021
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 17 Jun 2021 New trial record
- 01 May 2021 Results published in the Neoplasma